Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (1303)	2/4/2000 3:41:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 2001

Cheryl, Thanks, I just printed out a copy of it and perused it. What's the most interesting to me is that their price target of $25 is based on a 7.5 multiple of revenues. I believe biotechnology firms have an average multiple greater than 20. And this is for ADCON revenues alone. If Perceptin works out well and a deal is made, $75 is not an unreasonable valuation. I'm heading for a very simple portfolio. About 50% GLIA and about 50% NBIX with a few little odds and ends thrown in. Sometimes I buy 1,000 shares of an issue just to remind me to pay attention to them. The market is a wonderful reminder service.... Thanks, Torben